Alivus Life Sciences Acquires 76% Stake in IQGEN-X Pharma

Key Highlights Alivus Life Sciences has received Board approval to acquire a 76% stake in IQGEN-X Pharma for approximately ₹9.12 Crore in cash. The acquisition is aimed at strengthening Alivus' capabilities across formulation development and its API & CDMO segments. Transaction Details • Stake Acquired: 76% of IQGEN-X Pharma's paid-up equity capital. • Consideration: Approximately ₹9.12 Crore, payable in cash. • The transaction involves 8,60,589 equity shares. • IQGEN-X Pharma develops formulations across Oral Solids, Sterile Injectables and Ophthalmic solutions. • FY26 Turnover: ₹3.48 Crore vs ₹3.18 Crore in FY25 and ₹2.68 Crore in FY24. • The transaction is at arm's length, with no related-party or promoter interest. What It Means • The acquisition expands Alivus Life Sciences' formulation development capabilities. • Access to Oral Solids, Sterile Injectables and Ophthalmic solutions can complement its existing API and CDMO capabilities. • The transaction supports Alivus' strategy of offering end-to-end solutions across the pharmaceutical value chain. • IQGEN-X Pharma has reported consistent turnover growth over the past three financial years. Market Impact Impact: Neutral to Positive The acquisition strengthens Alivus Life Sciences' capabilities across formulation development and could support its end-to-end API and CDMO offering. However, the acquired company's FY26 turnover of ₹3.48 Crore indicates that the immediate financial contribution is relatively limited based on the information provided. Learning Outcome An acquisition allows a company to obtain an existing business, its capabilities, technology, customers or expertise rather than developing them internally. Investors should assess both the strategic fit and the financial contribution of the acquired company when evaluating such transactions.